ARCHIMMUNE
Live / Applied — Fifth extension granted (statement of use) (as of 27 Aug 2025)
What this means for you
Not registered yet, but its 21 Feb 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97276905
- Mark type
- Stylized text
- Filed
- 21 Feb 2022
- Published for opposition
- 10 Jan 2023
- Attorney of record
- Perry Gattegno
Goods and services
- Class 042 — Scientific and technological services: Consulting services in the field of biotechnology; Consulting services in the field of pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Biochemical research and development; Consulting services in the field of pharmacogenetics; Pharmaceutical research and development; Scientific research and development; Vaccine research and development
Owner
- Archimmune Therapeutics Inc., Lexington, MA, US
- Archimmune Therapeutics Inc., Lexington, MA, US
Prosecution history
- 27 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Aug 2025 — SOU EXTENSION 5 GRANTED
- 17 Aug 2025 — SOU EXTENSION 5 FILED
- 18 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Feb 2025 — SOU EXTENSION 4 GRANTED
- 24 Feb 2025 — SOU EXTENSION 4 FILED
- 24 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 27 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Aug 2024 — SOU EXTENSION 3 GRANTED
- 27 Aug 2024 — SOU EXTENSION 3 FILED
- 27 Aug 2024 — SOU TEAS EXTENSION RECEIVED
- 07 Feb 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Feb 2024 — SOU EXTENSION 2 GRANTED
- 05 Feb 2024 — SOU EXTENSION 2 FILED